Cancer vaccines could transform treatment and prevention
Moderna and Merck have reported success in a late-stage clinical trial for a personalized mRNA cancer vaccine for melanoma. However, researchers warn that misinformation regarding mRNA technology could hinder public adoption.
Why it matters
This represents a significant medical breakthrough in cancer treatment, though public health communication remains a challenge due to lingering vaccine skepticism.
For the first time, an mRNA cancer vaccine has succeeded in a late-stage clinical trial, a significant advance that could reshape how cancer is treated.
On Aug. 19, 2026, Moderna and Merck announced that their personalized vaccine, intismeran autogene, succeeded in reducing the recurrence of the skin cancer melanoma when combined with the immunotherapy drug Keytruda.
While these results could open the door to a wave of cancer vaccines, misinformation about mRNA technology circulating since the COVID-19 pandemic could undermine its momentum before it reaches patients.
The progress toward vaccines to treat cancer has been building for years. Since the early 2000s, there have been over 120 promising clinical trials testing the use of mRNA vaccines to treat multiple cancer types, such as melanoma , brain , breast , lung and prostate cancer.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in